Argenica Therapeutics' AI-Driven Reanalysis of Phase 2 Stroke Trial Shows Commercially Meaningful Benefit, Says Euroz Hartleys

MT Newswires Live12-12

Argenica Therapeutics' (ASX:AGN) artificial intelligence-driven reanalysis of its phase 2 stroke trial provide compelling evidence of ARG-007's clinically and commercially meaningful benefit in patients with severe stroke, said Euroz Hartleys in a Thursday note.

The research firm said that the phase 2 trial has effectively served its purpose: to characterize the drug's activity and identify the patients most likely to benefit.

Euroz Hartleys believes that the totality of evidence is more than sufficient to justify advancing into a targeted phase 2b trial enriched for patients most likely to respond, thereby maximizing the probability of success.

Euroz Hartleys maintained its speculative buy rating on AGN with a price target of AU$1.30.

Argenica Therapeutics' shares fell past 3% in recent Friday trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2590192524?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-12 12:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590192524","market":"fut","top_or_hot":-1,"title":"Argenica Therapeutics' AI-Driven Reanalysis of Phase 2 Stroke Trial Shows Commercially Meaningful Benefit, Says Euroz Hartleys","media":"MT Newswires Live","content":"<html><body><p> Argenica <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' (ASX:AGN) artificial intelligence-driven reanalysis of its phase 2 stroke trial provide compelling evidence of ARG-007's clinically and commercially meaningful benefit in patients with severe stroke, said <a href=\"https://laohu8.com/S/EZL.AU\">Euroz</a> Hartleys in a Thursday note.</p><p>The research firm said that the phase 2 trial has effectively served its purpose: to characterize the drug's activity and identify the patients most likely to benefit.</p><p>Euroz Hartleys believes that the totality of evidence is more than sufficient to justify advancing into a targeted phase 2b trial enriched for patients most likely to respond, thereby maximizing the probability of success.</p><p>Euroz Hartleys maintained its speculative buy rating on AGN with a price target of AU$1.30.</p><p>Argenica Therapeutics' shares fell past 3% in recent Friday trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Argenica Therapeutics' AI-Driven Reanalysis of Phase 2 Stroke Trial Shows Commercially Meaningful Benefit, Says Euroz Hartleys</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArgenica Therapeutics' AI-Driven Reanalysis of Phase 2 Stroke Trial Shows Commercially Meaningful Benefit, Says Euroz Hartleys\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-12 12:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Argenica <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' (ASX:AGN) artificial intelligence-driven reanalysis of its phase 2 stroke trial provide compelling evidence of ARG-007's clinically and commercially meaningful benefit in patients with severe stroke, said <a href=\"https://laohu8.com/S/EZL.AU\">Euroz</a> Hartleys in a Thursday note.</p><p>The research firm said that the phase 2 trial has effectively served its purpose: to characterize the drug's activity and identify the patients most likely to benefit.</p><p>Euroz Hartleys believes that the totality of evidence is more than sufficient to justify advancing into a targeted phase 2b trial enriched for patients most likely to respond, thereby maximizing the probability of success.</p><p>Euroz Hartleys maintained its speculative buy rating on AGN with a price target of AU$1.30.</p><p>Argenica Therapeutics' shares fell past 3% in recent Friday trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7096","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2590192524","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590192524","pubTimestamp":1765512212,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Argenica Therapeutics'  artificial intelligence-driven reanalysis of its phase 2 stroke trial provide compelling evidence of ARG-007's clinically and commercially meaningful benefit in patients with severe stroke, said Euroz Hartleys in a Thursday note.The research firm said that the phase 2 trial has effectively served its purpose: to characterize the drug's activity and identify the patients most likely to benefit.Euroz Hartleys believes that the totality of evidence is more than sufficient to justify advancing into a targeted phase 2b trial enriched for patients most likely to respond, thereby maximizing the probability of success.Euroz Hartleys maintained its speculative buy rating on AGN with a price target of AU$1.30.Argenica Therapeutics' shares fell past 3% in recent Friday trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7096":"制药","BK4539":"次新股","BK4007":"制药","BK4139":"生物科技","AGN.AU":"Argenica Therapeutics Ltd","LENZ":"Therapeutics"},"translate_title":"Euroz Hartleys表示，Argenica Therapeutics对2期中风试验的人工智能驱动再分析显示出具有商业意义的益处","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1.5,"AGN.AU":1},"content_text":"Argenica Therapeutics' (ASX:AGN) artificial intelligence-driven reanalysis of its phase 2 stroke trial provide compelling evidence of ARG-007's clinically and commercially meaningful benefit in patients with severe stroke, said Euroz Hartleys in a Thursday note.The research firm said that the phase 2 trial has effectively served its purpose: to characterize the drug's activity and identify the patients most likely to benefit.Euroz Hartleys believes that the totality of evidence is more than sufficient to justify advancing into a targeted phase 2b trial enriched for patients most likely to respond, thereby maximizing the probability of success.Euroz Hartleys maintained its speculative buy rating on AGN with a price target of AU$1.30.Argenica Therapeutics' shares fell past 3% in recent Friday trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2590192524","isCrawlerRequest":true}